Covered recipient · General Payments record
MIGUEL ANGEL ISLAS-OHLMAYER
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$7,439.87
6 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $7,109.00 | 3 |
| Food and Beverage | $330.87 | 3 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $4,029.00 | 2 |
| SOBI, INC | $3,203.97 | 2 |
| Rigel Pharmaceuticals, Inc. | $206.90 | 2 |
Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MIGUEL ANGEL ISLAS-OHLMAYER
NPI 1295917425 · CMS profile ID 59223
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
EDGEWOOD, KY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1295917425?year=2024&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MIGUEL ANGEL ISLAS-OHLMAYER, NPI 1295917425, CMS profile ID 59223. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295917425?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). MIGUEL ANGEL ISLAS-OHLMAYER, NPI 1295917425, CMS profile ID 59223. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295917425?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- MIGUEL ANGEL ISLAS-OHLMAYER, NPI 1295917425, CMS profile ID 59223, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1295917425?year=2024&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
6 matching records · $7,439.87 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–6 of 6.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,300.00 | 12/02/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101424298 | CMS |
| Rigel Pharmaceuticals, Inc. | $105.84 | 11/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145208193 | CMS |
| SOBI, INC | $3,080.00 | 11/08/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141433743 | CMS |
| SOBI, INC | $123.97 | 10/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141437005 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,729.00 | 05/14/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101424252 | CMS |
| Rigel Pharmaceuticals, Inc. | $101.06 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145200835 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $395.50 | 1 |
| PY2025 | Principal investigator | $58,459.40 | 2 |
| PY2024 | Recipient | $1,306.60 | 1 |
| PY2024 | Principal investigator | $113,571.67 | 2 |
| PY2023 | Recipient | $168.05 | 1 |
| PY2023 | Principal investigator | $315,531.55 | 45 |
| PY2022 | Principal investigator | $368,128.77 | 124 |
| PY2021 | Principal investigator | $257,202.74 | 115 |
| PY2020 | Principal investigator | $150,989.86 | 62 |
| PY2019 | Recipient | $7,317.30 | 2 |
| PY2019 | Principal investigator | $200,492.20 | 48 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
124 records in PY2022
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $58.00 | 12/31/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma | No dispute reported | 06/30/2026 | 965539771 |
| Principal investigator 1 | TG Therapeutics, Inc. | $426.30 | 12/31/2022 | Non-covered Recipient Entity Oncology Hematology Care Clinical Trials | A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 938735511 |
| Principal investigator 1 | TG Therapeutics, Inc. | $426.30 | 12/31/2022 | Non-covered Recipient Entity Oncology Hematology Care Clinical Trials | A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 938735519 |
| Principal investigator 1 | TG Therapeutics, Inc. | $550.00 | 12/30/2022 | Non-covered Recipient Entity Oncology Hematology Care Clinical Trials | A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 938735513 |
| Principal investigator 1 | TG Therapeutics, Inc. | $3,825.00 | 12/30/2022 | Non-covered Recipient Entity Oncology Hematology Care Clinical Trials | A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 938735515 |
| Principal investigator 1 | TG Therapeutics, Inc. | $550.00 | 12/30/2022 | Non-covered Recipient Entity Oncology Hematology Care Clinical Trials | A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 938735517 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $9,001.00 | 12/27/2022 | Non-covered Recipient Entity US Oncology Research, LLC | A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9) | No dispute reported | 06/30/2026 | 960375493 |
| Principal investigator 1 | ADC Therapeutics America, Inc. | $8,500.00 | 12/27/2022 | Non-covered Recipient Entity US Oncology Research, LLC | A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9) | No dispute reported | 06/30/2026 | 960375499 |
| Principal investigator 1 | Seagen Inc. | $250.00 | 12/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902887 |
| Principal investigator 1 | Seagen Inc. | $3,827.00 | 11/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902875 |
| Principal investigator 1 | Genentech, Inc. | $2,338.00 | 10/15/2022 | Non-covered Recipient Entity ONCOLOGY/ HEMATOLOGY CARE, INC. | POLARIX | No dispute reported | 06/30/2026 | 950693187 |
| Principal investigator 1 | MorphoSys AG | $956.00 | 10/15/2022 | Non-covered Recipient Entity ONCOLOGY/ HEMATOLOGY CARE, INC. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind | No dispute reported | 06/30/2026 | 954397441 |
| Principal investigator 1 | MorphoSys AG | $312.00 | 10/15/2022 | Non-covered Recipient Entity ONCOLOGY/ HEMATOLOGY CARE, INC. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind | No dispute reported | 06/30/2026 | 954397443 |
| Principal investigator 1 | Seagen Inc. | $956.00 | 10/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression | No dispute reported | 06/30/2026 | 917902669 |
| Principal investigator 1 | Seagen Inc. | $956.00 | 10/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917903099 |
| Principal investigator 1 | Seagen Inc. | $956.00 | 10/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917903105 |
| Principal investigator 1 | Incyte Corporation | $30,145.80 | 09/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE, INC. | A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 | No dispute reported | 06/30/2026 | 905223157 |
| Principal investigator 1 | MorphoSys AG | $150.00 | 09/15/2022 | Non-covered Recipient Entity ONCOLOGY/ HEMATOLOGY CARE, INC. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind | No dispute reported | 06/30/2026 | 954397431 |
| Principal investigator 1 | MorphoSys AG | $150.00 | 09/15/2022 | Non-covered Recipient Entity ONCOLOGY/ HEMATOLOGY CARE, INC. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind | No dispute reported | 06/30/2026 | 954397439 |
| Principal investigator 1 | Seagen Inc. | $718.00 | 09/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902179 |
| Principal investigator 1 | Seagen Inc. | $589.00 | 09/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902185 |
| Principal investigator 1 | Seagen Inc. | $150.00 | 09/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902193 |
| Principal investigator 1 | Seagen Inc. | $150.00 | 09/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902315 |
| Principal investigator 1 | Seagen Inc. | $589.00 | 09/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902327 |
| Principal investigator 1 | Seagen Inc. | $150.00 | 09/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902345 |
| Principal investigator 1 | Seagen Inc. | $589.00 | 09/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902357 |
| Principal investigator 1 | Seagen Inc. | $150.00 | 09/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902363 |
| Principal investigator 1 | MorphoSys AG | $250.00 | 08/15/2022 | Non-covered Recipient Entity ONCOLOGY/ HEMATOLOGY CARE, INC. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind | No dispute reported | 06/30/2026 | 954397425 |
| Principal investigator 1 | MorphoSys AG | $150.00 | 08/15/2022 | Non-covered Recipient Entity ONCOLOGY/ HEMATOLOGY CARE, INC. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind | No dispute reported | 06/30/2026 | 954397427 |
| Principal investigator 1 | MorphoSys AG | $2,081.00 | 08/15/2022 | Non-covered Recipient Entity ONCOLOGY/ HEMATOLOGY CARE, INC. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind | No dispute reported | 06/30/2026 | 954397429 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $1,200.00 | 08/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma | No dispute reported | 06/30/2026 | 890237673 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $1,200.00 | 08/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma | No dispute reported | 06/30/2026 | 890237679 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $1,200.00 | 08/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma | No dispute reported | 06/30/2026 | 890237681 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $1,200.00 | 08/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma | No dispute reported | 06/30/2026 | 890237683 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $1,250.00 | 08/03/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma | No dispute reported | 06/30/2026 | 890237537 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $1,250.00 | 08/03/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma | No dispute reported | 06/30/2026 | 890237545 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $1,250.00 | 08/03/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma | No dispute reported | 06/30/2026 | 890237547 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $1,250.00 | 08/03/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma | No dispute reported | 06/30/2026 | 890237549 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $1,250.00 | 08/03/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma | No dispute reported | 06/30/2026 | 890237551 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $2,159.14 | 07/27/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma | No dispute reported | 06/30/2026 | 890237485 |
| Principal investigator 1 | MorphoSys AG | $1,600.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY/ HEMATOLOGY CARE, INC. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind | No dispute reported | 06/30/2026 | 954397419 |
| Principal investigator 1 | MorphoSys AG | $956.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY/ HEMATOLOGY CARE, INC. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind | No dispute reported | 06/30/2026 | 954397421 |
| Principal investigator 1 | MorphoSys AG | $1,600.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY/ HEMATOLOGY CARE, INC. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind | No dispute reported | 06/30/2026 | 954397433 |
| Principal investigator 1 | MorphoSys AG | $1,600.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY/ HEMATOLOGY CARE, INC. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind | No dispute reported | 06/30/2026 | 954397435 |
| Principal investigator 1 | MorphoSys AG | $1,600.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY/ HEMATOLOGY CARE, INC. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind | No dispute reported | 06/30/2026 | 954397437 |
| Principal investigator 1 | Seagen Inc. | $150.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901997 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902015 |
| Principal investigator 1 | Seagen Inc. | $127.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917902021 |
| Principal investigator 1 | Seagen Inc. | $956.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902027 |
| Principal investigator 1 | Seagen Inc. | $60.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917902045 |
| Principal investigator 1 | Seagen Inc. | $589.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902051 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902081 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902087 |
| Principal investigator 1 | Seagen Inc. | $400.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917902403 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902413 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902419 |
| Principal investigator 1 | Seagen Inc. | $127.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917902431 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902437 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902443 |
| Principal investigator 1 | Seagen Inc. | $956.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917902449 |
| Principal investigator 1 | Seagen Inc. | $127.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917902459 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902471 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902477 |
| Principal investigator 1 | Seagen Inc. | $956.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression | No dispute reported | 06/30/2026 | 917902483 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902489 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 07/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917902495 |
| Principal investigator 1 | Seagen Inc. | $234.00 | 06/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917901679 |
| Principal investigator 1 | Seagen Inc. | $1,856.00 | 06/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917901691 |
| Principal investigator 1 | Seagen Inc. | $795.00 | 06/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917901697 |
| Principal investigator 1 | Seagen Inc. | $4,088.00 | 06/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917901703 |
| Principal investigator 1 | Seagen Inc. | $25.00 | 06/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917901713 |
| Principal investigator 1 | Seagen Inc. | $718.00 | 06/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901725 |
| Principal investigator 1 | Seagen Inc. | $59.00 | 06/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917901737 |
| Principal investigator 1 | Seagen Inc. | $530.00 | 06/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917901743 |
| Principal investigator 1 | Seagen Inc. | $200.00 | 06/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917901749 |
| Principal investigator 1 | Seagen Inc. | $150.00 | 06/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901775 |
| Principal investigator 1 | Seagen Inc. | $33.00 | 06/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917901781 |
| Principal investigator 1 | Seagen Inc. | $31.00 | 06/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917901787 |
| Principal investigator 1 | Seagen Inc. | $1,650.00 | 06/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917901799 |
| Principal investigator 1 | Seagen Inc. | $40.00 | 06/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917901805 |
| Principal investigator 1 | Seagen Inc. | $718.00 | 06/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901957 |
| Principal investigator 1 | Seagen Inc. | $150.00 | 06/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901973 |
| Principal investigator 1 | Seagen Inc. | $40.00 | 06/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917901979 |
| Principal investigator 1 | Seagen Inc. | $27,825.00 | 06/01/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917902813 |
| Principal investigator 1 | Seagen Inc. | $27,825.00 | 05/17/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917902807 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 05/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901657 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 05/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901939 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 05/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901945 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 05/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901951 |
| Principal investigator 1 | Genentech, Inc. | $1,375.00 | 05/05/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | POLARIX | No dispute reported | 06/30/2026 | 950738293 |
| Principal investigator 1 | Genentech, Inc. | $1,375.00 | 05/05/2022 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | POLARIX | No dispute reported | 06/30/2026 | 950738299 |
| Principal investigator 1 | Genentech, Inc. | $2,338.00 | 04/15/2022 | Non-covered Recipient Entity ONCOLOGY/ HEMATOLOGY CARE, INC. | POLARIX | No dispute reported | 06/30/2026 | 950729623 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $1,063.00 | 04/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma | No dispute reported | 06/30/2026 | 890236569 |
| Principal investigator 1 | Seagen Inc. | $956.00 | 04/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression | No dispute reported | 06/30/2026 | 917901627 |
| Principal investigator 1 | Seagen Inc. | $956.00 | 04/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901915 |
| Principal investigator 1 | Seagen Inc. | $956.00 | 04/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917901921 |
| Principal investigator 1 | TG Therapeutics, Inc. | $700.00 | 04/01/2022 | Non-covered Recipient Entity US Oncology Research, LLC | A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 938733055 |
| Principal investigator 1 | TG Therapeutics, Inc. | $500.00 | 04/01/2022 | Non-covered Recipient Entity US Oncology Research, LLC | UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkins Lymphoma | No dispute reported | 06/30/2026 | 938733293 |
| Principal investigator 1 | TG Therapeutics, Inc. | $500.00 | 04/01/2022 | Non-covered Recipient Entity US Oncology Research, LLC | UNITY-NHL: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkins Lymphoma | No dispute reported | 06/30/2026 | 938733295 |
| Principal investigator 1 | TG Therapeutics, Inc. | $700.00 | 04/01/2022 | Non-covered Recipient Entity US Oncology Research, LLC | A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 938733477 |
| Principal investigator 1 | PFIZER INC. | $17,497.73 | 03/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED ACTIVECOMPARATOR MULTICENTER PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN OR PLACEBO IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE BCELL LYMPHOMA DLBCL | No dispute reported | 06/30/2026 | 1130864797 |
| Principal investigator 1 | Seagen Inc. | $589.00 | 03/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901595 |
| Principal investigator 1 | Seagen Inc. | $150.00 | 03/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901605 |
| Principal investigator 1 | Seagen Inc. | $250.00 | 03/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901611 |
| Principal investigator 1 | Seagen Inc. | $589.00 | 03/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901887 |
| Principal investigator 1 | Seagen Inc. | $150.00 | 03/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901893 |
| Principal investigator 1 | Celgene Corporation | $9,420.00 | 02/15/2022 | Non-covered Recipient Entity Ohc Mercy West | A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma | No dispute reported | 06/30/2026 | 937186311 |
| Principal investigator 2 | Celgene Corporation | $109,674.50 | 02/01/2022 | Non-covered Recipient Entity Us Oncology Res Llc | A Phase 3B Randomized Study of Lenalidomide (CC-50 | No dispute reported | 06/30/2026 | 937183965 |
| Principal investigator 1 | TG Therapeutics, Inc. | $450.00 | 01/31/2022 | Non-covered Recipient Entity US Oncology Research, LLC | A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 938733059 |
| Principal investigator 1 | TG Therapeutics, Inc. | $450.00 | 01/31/2022 | Non-covered Recipient Entity US Oncology Research, LLC | A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 938733479 |
| Principal investigator 1 | Incyte Corporation | $1,125.00 | 01/24/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE, INC. | A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 | No dispute reported | 06/30/2026 | 905223111 |
| Principal investigator 1 | Incyte Corporation | $956.00 | 01/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE, INC. | A Phase 2, Open Label, 2 Cohort, Multicenter Study of INCB050465, a PI3Kd Inhibitor in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor, CITADEL 205 | No dispute reported | 06/30/2026 | 905223135 |
| Principal investigator 1 | MorphoSys AG | $956.00 | 01/15/2022 | Non-covered Recipient Entity ONCOLOGY/ HEMATOLOGY CARE, INC. | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) - Front Mind | No dispute reported | 06/30/2026 | 954397377 |
| Principal investigator 1 | Pharmacyclics LLC, an AbbVie Company | $1,063.00 | 01/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | Study of Ibrutinib and Rituximab in Treatment Nave Follicular Lymphoma | No dispute reported | 06/30/2026 | 890235949 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 01/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901552 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 01/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901829 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 01/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901835 |
| Principal investigator 1 | Seagen Inc. | $956.00 | 01/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901847 |
| Principal investigator 1 | Seagen Inc. | $956.00 | 01/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression | No dispute reported | 06/30/2026 | 917901853 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 01/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901859 |
| Principal investigator 1 | Seagen Inc. | $956.00 | 01/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | No dispute reported | 06/30/2026 | 917901863 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 01/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901869 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 01/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901985 |
| Principal investigator 1 | Seagen Inc. | $2,211.00 | 01/15/2022 | Non-covered Recipient Entity ONCOLOGY HEMATOLOGY CARE INC | A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD | No dispute reported | 06/30/2026 | 917901991 |